Sobi, Inc. is an international biopharmaceutical company dedicated to rare diseases, with a focus in immunology, hemophilia, inflammatory, genetic, and metabolic diseases. Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants aged <1 year. High-risk populations include infants and children who are born prematurely and those with chronic lung disease or congenital heart disease. RSV hospitalizations in preterm infants have been increasing since 2014 and often result in ICU admission and the need for mechanical ventilation.